Macrae Sandy 4

What Happened

• Sandy Macrae, President, CEO and Director of Sangamo Therapeutics (SGMO), surrendered 102,950 shares on Jan 22, 2026 to satisfy mandatory tax withholding on vested restricted stock units (RSUs). The filing reports the shares at $0.40 each (closing price used: $0.3985), for a cash value to the company of approximately $41,026. This was a withholding disposition to the issuer (transaction code F), not an open-market sale.

Key Details

• Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (timely filing).
• Shares surrendered/disposed: 102,950; reported price: $0.40/share (issuer closing price used: $0.3985); total value ≈ $41,026.
• Transaction type: F (shares withheld by issuer to cover tax withholding on vested RSUs) — not a discretionary sale.
• Footnote F1: Surrender was solely for mandatory tax withholding and is deemed a disposition for reporting; not an open-market trade.
• Footnote F2: Notes RSU-related details — e.g., 147,050 shares vested from a Jan 22, 2024 RSU tranche on Jan 22, 2026, plus other RSU grants with future vesting schedules (details in filing). Vesting is subject to continuous service and possible acceleration per the plan.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• This is a routine tax-withholding transaction triggered by RSU vesting. Such surrenders reduce the number of net new shares delivered to the insider but do not reflect a discretionary sale or market sentiment. The dollar amount (~$41k) is modest relative to typical insider trades.